| Bioactivity | Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough[1][2]. | ||||||||||||
| Target | IC50: 8 nM (P2X3 receptor) | ||||||||||||
| In Vivo | Eliapixant can be used for the research of coughs and diabetes complications[1]. | ||||||||||||
| Name | Eliapixant | ||||||||||||
| CAS | 1948229-21-7 | ||||||||||||
| Formula | C22H21F3N4O3S | ||||||||||||
| Molar Mass | 478.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Spinaci A, et, al. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Front Pharmacol. 2021 Apr 13;12:653561. [2]. Morice A, et, al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240. |
Eliapixant
CAS: 1948229-21-7 F: C22H21F3N4O3S W: 478.49
Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.